Loading…

New quinoxaline-2(1)-ones as potential VEGFR-2 inhibitors: design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations

Eleven new quinoxaline derivatives were designed and synthesized as modified VEGFR-2 inhibitors of our previous work. The synthesized compounds were tested against three human cancer cell lines (HepG-2, MCF-7 and HCT-116). Compounds 11g , 11e and 11c were the most potent members against the tested c...

Full description

Saved in:
Bibliographic Details
Published in:New journal of chemistry 2021-09, Vol.45 (36), p.16949-16964
Main Authors: Yousef, Reda G, Sakr, Helmy M, Eissa, Ibrahim H, Mehany, Ahmed. B. M, Metwaly, Ahmed M, Elhendawy, Mostafa A, Radwan, Mohamed M, ElSohly, Mahmoud A, Abulkhair, Hamada S, El-Adl, Khaled
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eleven new quinoxaline derivatives were designed and synthesized as modified VEGFR-2 inhibitors of our previous work. The synthesized compounds were tested against three human cancer cell lines (HepG-2, MCF-7 and HCT-116). Compounds 11g , 11e and 11c were the most potent members against the tested cells. Compound 11g (IC 50 = 4.50, 2.40, and 5.90 μM) was the most potent member compared to doxorubicin (IC 50 = 8.29, 9.65, and 7.68 μM) and sorafenib (IC 50 = 7.33, 9.41, and 7.23 μM) against HepG-2 and HCT-116, and MCF-7 cell lines, respectively. Compound 11e showed better anti-proliferative activities than doxorubicin and sorafenib with IC 50 values of 5.34, 4.19, and 6.06 μM, against HepG-2 and HCT-116 and MCF-7 cell lines, respectively. In addition, the most active anti-proliferative derivatives 11c , 11e , 11f , and 11g were selected to evaluate their inhibitory activities against VEGFR-2. The tested compounds displayed good inhibitory activity with IC 50 values ranging from 0.75 to 1.36 μM. Among them, compound 11g was the most active member with an IC 50 value of 0.75 μM, compared to the reference drug; sorafenib (IC 50 = 1.29 μM). Moreover, docking studies revealed that the synthesized compounds have good binding patterns against the prospective molecular target; VEGFR-2. In addition, in silico , ADMET and toxicity studies showed a high level of drug likeness for the synthesized compounds. Eleven new quinoxaline derivatives were designed and synthesized as modified VEGFR-2 inhibitors of our previous work.
ISSN:1144-0546
1369-9261
DOI:10.1039/d1nj02509k